HK1251864A1 - 對atp結合位點進行突變的血管內皮抑制素突變體 - Google Patents

對atp結合位點進行突變的血管內皮抑制素突變體

Info

Publication number
HK1251864A1
HK1251864A1 HK18110856.2A HK18110856A HK1251864A1 HK 1251864 A1 HK1251864 A1 HK 1251864A1 HK 18110856 A HK18110856 A HK 18110856A HK 1251864 A1 HK1251864 A1 HK 1251864A1
Authority
HK
Hong Kong
Prior art keywords
mutates
binding sites
vascular endothelial
atp binding
myostatin mutant
Prior art date
Application number
HK18110856.2A
Other languages
English (en)
Inventor
羅永章
劉鵬
魯薪安
陳陽
付彥
常國棟
周代福
Original Assignee
清華大學
北京普羅吉生物科技發展有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 清華大學, 北京普羅吉生物科技發展有限公司 filed Critical 清華大學
Publication of HK1251864A1 publication Critical patent/HK1251864A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
HK18110856.2A 2011-09-09 2018-08-23 對atp結合位點進行突變的血管內皮抑制素突變體 HK1251864A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201110280441 2011-09-09
PCT/CN2012/081210 WO2013034116A1 (zh) 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体

Publications (1)

Publication Number Publication Date
HK1251864A1 true HK1251864A1 (zh) 2019-04-26

Family

ID=47831548

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110856.2A HK1251864A1 (zh) 2011-09-09 2018-08-23 對atp結合位點進行突變的血管內皮抑制素突變體

Country Status (10)

Country Link
US (1) US10647968B2 (zh)
EP (1) EP2754718B1 (zh)
JP (1) JP6336389B2 (zh)
CN (2) CN108291248B (zh)
AU (1) AU2012306826B2 (zh)
CA (1) CA2848118C (zh)
HK (1) HK1251864A1 (zh)
IL (1) IL231419A0 (zh)
RU (1) RU2014113924A (zh)
WO (1) WO2013034116A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104926933B (zh) * 2014-03-19 2018-09-07 北京仁和天通生物科技有限公司 Endostatin突变体、Endostatin突变体与聚乙二醇的交联物以及它们的应用
AU2015342324B2 (en) * 2014-11-03 2021-08-19 Beijing Protgen Ltd. Drug for inhibiting adipose cell differentiation and insulin resistance
JP6896636B2 (ja) * 2015-02-13 2021-06-30 清華大学Tsinghua University 組換えタンパク質薬の分子設計
CN106674352B (zh) * 2015-11-10 2020-05-15 孙嘉琳 抗肿瘤蛋白内皮抑素的衍生物及应用
CN109963597B (zh) * 2016-11-10 2022-08-26 北京普罗吉生物科技发展有限公司 聚乙二醇化血管内皮抑制素类似物及其应用
JP7492687B2 (ja) * 2017-07-30 2024-05-30 清華大学 Dna-pkcsを阻害するための薬物治療
CN114645025B (zh) * 2022-04-13 2023-12-22 南开大学 一种人源atp合成酶的纯化方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2313705A1 (en) * 1997-12-08 1999-06-17 Beth Israel Deaconess Medical Center Restin and methods of use thereof
WO2000067771A1 (en) * 1999-05-06 2000-11-16 The Burnham Institute Antiangiogenic endostatin peptides, endostatin variants and methods of use
CN1237072C (zh) 2000-05-22 2006-01-18 烟台荣昌生物工程有限公司 生产内皮抑制素的方法
JP4511108B2 (ja) 2002-05-31 2010-07-28 オンコリクス インコーポレイテッド ヒトプロラクチン拮抗剤−血管新生阻害剤融合蛋白質
CN100475270C (zh) * 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN101143894A (zh) * 2007-06-22 2008-03-19 中国药科大学 高效抑制血管生成多肽及其物理化学修饰方法和应用
EP2270055A4 (en) 2008-04-04 2011-06-29 Procell Therapeutics Inc CELLPERMEABLE RECOMBINANT ENDOSTATINE PROTEIN, POLYNUCLEOTIDE FOR ITS CODING AND ANTICIPATED PREPARATION WITH THE PROTEIN AS AN ACTIVE SUBSTANCE
CN101256139A (zh) 2008-04-18 2008-09-03 山东先声麦得津生物制药有限公司 一种血管内皮抑制素生物活性的检测方法
CN101890155B (zh) * 2010-05-25 2012-07-25 江苏先声药物研究有限公司 一种药物组合物及其应用

Also Published As

Publication number Publication date
CN117987505A (zh) 2024-05-07
CA2848118A1 (en) 2013-03-14
EP2754718B1 (en) 2017-12-13
US10647968B2 (en) 2020-05-12
RU2014113924A (ru) 2015-10-20
AU2012306826A1 (en) 2014-04-03
AU2012306826B2 (en) 2018-01-04
CA2848118C (en) 2023-09-05
JP2014531897A (ja) 2014-12-04
JP6336389B2 (ja) 2018-06-06
US20140308263A1 (en) 2014-10-16
WO2013034116A1 (zh) 2013-03-14
EP2754718A1 (en) 2014-07-16
CN108291248B (zh) 2024-03-08
US20150197733A9 (en) 2015-07-16
IL231419A0 (en) 2014-04-30
EP2754718A4 (en) 2015-04-22
CN108291248A (zh) 2018-07-17

Similar Documents

Publication Publication Date Title
IL263973B (en) Protein-polymer-drug conjugates
HK1251864A1 (zh) 對atp結合位點進行突變的血管內皮抑制素突變體
HK1200714A1 (zh) 粘合活性劑綴合物
HK1196257A1 (zh) -抗體結合物
IL228404A0 (en) Antibody-drug captures
EP2606072A4 (en) SYNERGISTIC BIOMOLECULAR POLYMER CONJUGATES
SI2609271T1 (sl) Blažilna naprava za dele pohištva
EP2754930A4 (en) sliding component
EP2754931A4 (en) SLIDING ELEMENT
EP2752603A4 (en) sliding component
HK1197090A1 (zh) 支撐構件
EP2752602A4 (en) SLIDING ELEMENT
IL231772A (en) Q ingredient is tethered to the tibia
EP2697943A4 (en) TRANSACTION GATEWAY
HK1195068A1 (zh) 拮抗劑
EP2720546A4 (en) TRPV4 Antagonist
EP2720697A4 (en) TRPV4 Antagonist
ZA201402936B (en) Prosthesis Component
PL2744371T3 (pl) Mebel
PL2741634T3 (pl) Mebel
HUP1100726A2 (en) Component
GB2492773B (en) Barricade component
ZA201104164B (en) Sulfamoyl-phenyl-ureido benzamidine-derivatives as antimalarial agents
PL2430948T3 (pl) Wyciąg szafy
AU4553P (en) WES04 Westringia fruticosa